A cell-level model of pharmacodynamics-mediated drug disposition
- PMID: 27612462
- DOI: 10.1007/s10928-016-9491-z
A cell-level model of pharmacodynamics-mediated drug disposition
Abstract
We aimed to develop a cell-level pharmacodynamics-mediated drug disposition (PDMDD) model to analyze in vivo systems where the PD response to a drug has an appreciable effect on the pharmacokinetics (PK). An existing cellular level model of PD stimulation was combined with the standard target-mediated drug disposition (TMDD) model and the resulting model structure was parametrically identifiable from typical in vivo PK and PD data. The PD model of the cell population was controlled by the production rate k in and elimination rate k out which could be stimulated or inhibited by the number of bound receptors on a single cell. Simulations were performed to assess the impact of single and repeated dosing on the total drug clearance. The clinical utility of the cell-level PDMDD model was demonstrated by fitting published data on the stimulatory effects of filgrastim on absolute neutrophil counts in healthy subjects. We postulated repeated dosing as a means of detecting and quantifying PDMDD as a single dose might not be sufficient to elicit the cellular response capable of altering the receptor pool to visibly affect drug disposition. In the absence of any PD effect, the model reduces down to the standard TMDD model. The applications of this model can be readily extended to include chemotherapy-induced cytopenias affecting clearance of endogenous hematopoietic growth factors, different monoclonal antibodies and immunogenicity effects on PK.
Keywords: Absolute neutrophil count; Cell populations; Filgrastim; Target-mediated drug disposition.
Similar articles
-
Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.Br J Clin Pharmacol. 2018 May;84(5):911-925. doi: 10.1111/bcp.13504. Epub 2018 Feb 20. Br J Clin Pharmacol. 2018. PMID: 29318653 Free PMC article.
-
Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.J Clin Pharmacol. 2010 Sep;50(9 Suppl):101S-112S. doi: 10.1177/0091270010376966. J Clin Pharmacol. 2010. PMID: 20881223
-
Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.J Clin Pharmacol. 2006 Jul;46(7):747-57. doi: 10.1177/0091270006288731. J Clin Pharmacol. 2006. PMID: 16809800 Clinical Trial.
-
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12. doi: 10.1517/17425250902992901. Expert Opin Drug Metab Toxicol. 2009. PMID: 19505189 Review.
-
Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.J Clin Pharmacol. 2020 Feb;60(2):149-163. doi: 10.1002/jcph.1545. Epub 2019 Dec 2. J Clin Pharmacol. 2020. PMID: 31793004 Free PMC article. Review.
Cited by
-
Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy.CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1319-1334. doi: 10.1002/psp4.13012. Epub 2023 Aug 9. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37559343 Free PMC article.
-
A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.J Pharmacokinet Pharmacodyn. 2020 Apr;47(2):163-182. doi: 10.1007/s10928-020-09680-6. Epub 2020 Mar 11. J Pharmacokinet Pharmacodyn. 2020. PMID: 32162138 Free PMC article.
-
Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.AAPS J. 2020 Jan 16;22(2):30. doi: 10.1208/s12248-019-0410-2. AAPS J. 2020. PMID: 31950308
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources